The Asensio Case Studies section highlights 15 examples from the Asensio record involving companies that Asensio & Company, Inc. investigated and shorted during its 8 years of existence. These cases represent the most dramatic and successful investments from the Asensio record. In each instance, the Asensio publication lowered the price of an overvalued company’s shares. The research publicized serious legal and regulatory issues concerning questionable public companies. At the same time, it helped journalists disseminate information to the public and gave investors free access to valuable investment analysis, protecting innocent people from making uninformed choices with their money.
Of the 15 companies described below, Asensio research reduced the price of 6 to nothing. In all, the Asensio reports lowered the combined market value of the 15 companies featured in this section by $20,269,405.
Click on each graph for a list of the Asensio reports.
|
 Investors may be buying Able shares believing that its recently acquired MFS Network Technologies subsidiary ("NT") possesses some value in excess of Able's purchase cost. In fact, some investors have no information concerning Able capital structure after the NT acquisition. Any information to the contrary is false and misleading. |
|
 Copy to be provided. |
|
 CTSC's situation is more a challenge to remain solvent rather than an opportunity to increase its already staggering $380 million market value. We see no possible future outcome that can remotely justify CTSC's current market value. We believe the shares would be overvalued at half their price. |
|
 Copy to be provided. |
|
 Contrary to management claims, Ergobilt's Fon'iks Writer is nothing new. In fact, it is digitext that has already been used by a new defunct stock promotion. |
|
 Copy to be provided. |
|
 Copy to be provided. |
|
 Copy to be provided. |
|
 Solv-Ex's plant is ill-designed and will not produce bitumen. Management is corrupt. We believe Solv-Ex's shares will soon be worthless. |
|
 We believe that Syquest's ability to remain in business is a far truer concern than whether its stock is nearly its current price. We further believe that the Company is most likely worth less than its liabilities, and that current equity holders will suffer significant dilution even if distress financing is made available. |
|
 Many of Diana's product claims are false. Diana possesses no valuable technology. Its shares are grossly overvalued. We believe they will quickly give-back all of their gains. |
|
 Turbodyne Technologies electric supercharger is an absurd product with little or no sales potential. |
|
 Copy to be provided. |
|
 Copy to be provided. |
|
 Zonagen is by all economic and financial measures grossly overvalued. We believe that this is a result of Zonagen's high selective disclosures concerning its Vasomax test results, promotion of its future prospects and failure to disclose material negative information. We believe that Zonagen's management has consistently misled investors about Vasomx's NDA filing deadlines, product efficacy and patent position. We see no possible realistic outcome that can justify Zonagen's current stock price. |
|
|
